Canada markets closed

Ocugen, Inc. (OCGN)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.2400-0.0100 (-0.80%)
At close: 04:00PM EST
1.2300 -0.01 (-0.81%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.2500
Open1.2500
Bid1.2200 x 41800
Ask1.2400 x 36900
Day's Range1.2100 - 1.2600
52 Week Range1.0900 - 4.5300
Volume5,011,979
Avg. Volume5,216,960
Market Cap271.42M
Beta (5Y Monthly)3.71
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Ocugen Appoints Quan A. Vu as Chief Business Officer

    MALVERN, Pa., Feb. 01, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced the appointment of Quan A. Vu as Chief Business Officer, responsible for securing new business development partnerships, including in/out licensing opportunities, across the Company’s pipeline. “Expanding Ocugen’s product portfolio and capabilities, in line w

  • GlobeNewswire

    Ocugen, Inc. to Present at 2023 BIO CEO & Investor Conference

    MALVERN, Pa., Jan. 31, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines, today announced that Dr. Shankar Musunuri, Chairman, Chief Executive Officer and Co-Founder of Ocugen will present at the BIO CEO & Investor Conference being held February 6-9, 2023, at the Marriott Marquis in New York City. Dr. Musunuri and members of Ocugen’s executive tea

  • GlobeNewswire

    Ocugen Announces Positive Top-Line Data for COVID-19 Vaccine Candidate COVAXIN™ (BBV152) in Phase 2/3 Immuno-bridging and Broadening Study: Both Co-primary Endpoints Met

    Study met both co-primary endpoints with robust immune responses COVAXIN™ was found to be well-tolerated in vaccine-naïve individuals and in individuals previously vaccinated with mRNA vaccines in the United States (U.S.), with no vaccine-related serious adverse events, thrombotic events, or cases of myocarditis or pericarditisThese data add to the body of evidence that COVAXIN™, an adjuvated whole SARS-CoV-2 virus inactivated vaccine, has been demonstrated to be well-tolerated and effective aga